Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 1050-1056

  Notermans, Daan W ^a,e   Pakker, Nadine G ^a   Hamann, Dörte ^a   Foudraine, Norbert A ^b   Kauffmann, Robert H ^d   Meenhorst, Pieter L ^c   Goudsmit, Jaap ^a   Roos, Marijke T L ^a   Schellekens, Peter T A ^a   Miedema, Frank ^a   Danner, Sven A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d LEYENBURG HOSPITAL   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; LAMIVUDINE; LYMPHOCYTE COUNT; LYMPHOCYTES; REFERENCE VALUES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; T-LYMPHOCYTES; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 0033394585     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315013     Document Type: Article

References (32)

1. De Wolf F, Spijkerman I, Schellekens PThA, et al. AIDS prognosis based on HIV-1 RNA, CD4 T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11:1799-806.
2. Roos MThL, Prins M, Koot M, et al. Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. AIDS 1998; 12:1745-51.
3. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg L. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995;95:2061-6.
4. + cell count, soluble immune activation markers, or combinations of HLA-DR und CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:83-92.
5. + lymphocyte percent: a useful immunological marker for monitoring HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:158-62.
6. Gruters RA, Terpstra FG, De Goede REY, et al. Immunological and virological markers in individuals progressing from seroconversion to AIDS. AIDS 1991;5:837-44.
7. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, Egeland T. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J Infect Dis 1994; 169:730-8.
8. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4.
9. Notermans DW, Jurriaans S, De Wolf F, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 1998; 12:167-73.
10. Notermans DW, Goudsmit J, Danner SA, De Wolf F, Perelson AS, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS 1998;12:1483-90.
11. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
12. Pakker NG, Notermans DW, De Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.
13. + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:1154-9.
14. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Longlasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-6.
15. Angel JH, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir and saquinavir J Infect Dis 1998; 177:898-904.
16. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV) infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173:321-9.
17. Lederman MM, Connick E, Landay A. et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine and ritonavir: results of AIDS Clinical Trials Group protocol 315. J Infect Dis 1998; 178:70-9.
18. + T-lymphocyte regeneration after intensive chemotherapy. New Engl J Med 1995;332:143-9.
19. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Gross-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996;88:2775-9.
20. Rep M, Van Oosten BW, Roos MTL, Ader HJ, Polman CH, Van Lier R. Treatment with depicting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-τ secreting TH1 cells in humans. J Clin Invest 1997;99:2225-31.
21. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998; 12:F123-9.
22. Foudraine NA, Hovenkamp E, Notermans DW, et al. Immunopathology us a result of highly active antiretroviral therapy in HIV-1 infected patients. AIDS 1999; 13:177-84.
23. Pontesilli O, Kerkhof-Garde SR, Notermans DW, et al. Functional T cell reconstitution and HIV-1-specific cell-mediated immunity during highly active antiretroviral therapy (HAART). J Infect Dis 1999 (in press).
24. Clark DR, Repping S, Pakker NG, et al. T-cell renewal impaired in HIV-1 infected individuals [abstract 22]. In: 6th conference on retroviruses and opportunistic infections (Chicago, IL), 1999.
25. McCune JM, Loftus R, Schmidt DK, et al. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998; 101:2301-8.
26. Douek DC, McFarland RD, Keiser RD, et al. Changes in thymic function with age and during the treatment of HIV infection, Nature 1998;396:690-5.
27. + T-cell repopulation kinetics during highly active antiretroviral therapy. AIDS 1998; 12:F235-40.
28. Renaud M, Katlama C, Mallet M, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-76.
29. Staszewski S, Miller V, Sabin C, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999; 13:951-6
30. + naive T cells following triple-drug therapy for HIV type 1 infection. AIDS Res Hum Retroviruses 1999; 5:435-43.
31. + lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998; 12:1267-73.
32. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet 1999; 353:119-20.